Castle Biosciences

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Our mission is to provide physicians and their patients with better-informed diagnostic and therapeutic decisions enabled by the use of proprietary genetic profiling technologies.

Our vision is to improve healthcare economics and patient outcomes by utilizing technology, precision medicine, and genomics-informed decision-making to revolutionize medical care.

Castle Biosciences has been recognized with numerous awards and accolades, including the 2017 Frost & Sullivan North American Life Science and Diagnostic Company of the Year Award and the Excellence in Clinical Science Achievement Award from the International Society for the Dermatology Outcomes Measurement .